Author

T. R. Rutherford

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

T. R. Lyons· 2 shared A. M. Elder· 1 shared G. L. Wyatt· 1 shared J. K. Richer· 1 shared L. S. Crump· 1 shared W. W. Porter· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

6 top collaborators · 11 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

T. R. Lyons

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Anoikis resistance in mammary epithelial cells is mediated by semaphorin-7a.

T. R. Rutherford, A. M. Elder, T. R. Lyons

This study shows SEMA7A promotes anoikis resistance in mammary epithelial cells via integrins and AKT, and its absence reduces luminal progenitor cells during involution, suggesting a role in breast cancer recurrence.

bioRxiv · Jun 28, 2021Cell Biology

Hormonal regulation of Semaphorin 7a in ER+ breast cancer drives therapeutic resistance

L. S. Crump, G. L. Wyatt, T. R. Rutherford, J. K. Richer, W. W. Porter, T. R. Lyons

This study identifies SEMA7A as a driver of therapeutic resistance in ER+ breast cancer and suggests targeting survival signaling pathways as a potential treatment strategy.

bioRxiv · Oct 5, 2020Cancer Biology